CONSTRUCTS OF UNION
Patent Information
- Application Number
- ARP20250100435
- Authority / Receiving Office
- AR · AR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-30
- Filing Date
- 2025-02-17
- Publication Date
- 2026-08-05
Claims
The invention provides inter alia a construction comprising a FAP bonding agent and an LTBR bonding agent.
1. A construction comprising a FAP bonding agent and an LTBR bonding agent.
19. A binding polypeptide comprising or consisting of a paired heavy chain variable domain and a light chain variable domain that binds to LTBR, wherein the heavy chain variable domain comprises or consists of three complementarity-determining regions (HCDR1 - HCDR3) and four framework regions (HFR1 - HFR4), wherein (a) HCDR1 comprises or consists of a polypeptide sequence of SEQ ID No. 69, HCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 70, and HCDR3 comprises or consists of a polypeptide sequence of SEQ ID No. 71, and the light chain variable domain comprises or consists of three complementarity-determining regions (LCDR1 - LCDR3) and four framework regions (LFR1 - LFR4), wherein LCDR1 comprises or consists of a polypeptide sequence of SEQ ID No. 72,LCDR2 comprises or comprises a polypeptide sequence of SEQ ID No. 73 and LCDR3 comprises or comprises a polypeptide sequence of SEQ ID No. 74; (b) HCDR1 comprises or comprises a polypeptide sequence of SEQ ID No. 75, HCDR2 comprises or comprises a polypeptide sequence of SEQ ID No. 76 and HCDR3 comprises or comprises a polypeptide sequence of SEQ ID No. 77 and the light chain variable domain or consists of three complementarity-determining regions (LCDR1 - LCDR3) and four framework regions (LFR1 - LFR4), wherein LCDR1 comprises or consists of a polypeptide sequence of SEQ ID No. 78, LCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 78 and SEQ ID No. 79 comprises or consists of a polypeptide sequence of SEQ ID No 80; (c) the HCDR1 comprises or consists of a polypeptide sequence of SEQ ID No. 81,HCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 82 and HCDR3 comprises or consists of a polypeptide sequence of SEQ ID No. 83 and the light chain variable domain comprises or consists of three complementarity determining regions (LCDR31) and four framework regions (LFR1 - LFR4), wherein LCDR1 comprises or consists of a polypeptide sequence of SEQ ID No. 84, LCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 85 and LCDR3 comprises or consists of a polypeptide sequence of SEQ ID No. 86; (d) the HCDR1 comprises or consists of a polypeptide sequence of SEQ ID No. 87,HCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 88 and HCDR3 comprises or consists of a polypeptide sequence of SEQ ID No. 89 and the light chain variable domain comprises or consists of three complementarity determining regions (LCDR31) and four framework regions (LFR1 - LFR4), wherein LCDR1 comprises or consists of a polypeptide sequence of SEQ ID No. 90, LCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 91 and LCDR3 comprises or consists of a polypeptide sequence of SEQ ID No. 92; (e) the HCDR1 comprises or consists of a polypeptide sequence of SEQ ID No 93,HCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 94 and HCDR3 comprises or consists of a polypeptide sequence of SEQ ID No. 95 and the light chain variable domain comprises or consists of three complementarity determining regions (LCDR31) and four framework regions (LFR1 - LFR4), wherein LCDR1 comprises or consists of a polypeptide sequence of SEQ ID No. 96, LCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 97 and LCDR3 comprises or consists of a polypeptide sequence of SEQ ID No. 98; (f) the HCDR1 comprises or consists of a polypeptide sequence of SEQ ID No. 99,the HCDR2 comprises or consists of a polypeptide sequence of SEQ ID No 100 and the HCDR3 comprises or consists of a polypeptide sequence of SEQ ID No 101 and the light chain variable domain comprises or consists of three complementarity-determining regions (LCDR31) and four framework regions (LFR1 - LFR4), wherein LCDR1 comprises or consists of a polypeptide sequence of SEQ ID No. 102, LCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 103 and LCDR3 comprises or consists of a polypeptide sequence of SEQ ID No. 104; (g) the HCDR1 comprises or consists of a polypeptide sequence of SEQ ID No 105,HCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 106 and HCDR3 comprises or consists of a polypeptide sequence of SEQ ID No. 107 and the light chain variable domain comprises or consists of three complementarity-determining regions (LCDR31) and four framework regions (LFR1 - LFR4), wherein LCDR1 comprises or consists of a polypeptide sequence of SEQ ID No. 108, LCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 109 and LCDR3 comprises or consists of a polypeptide sequence of SEQ ID No. 10; or (h) the HCDR1 comprises or consists of a polypeptide sequence of SEQ ID No 111,HCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 112 and HCDR3 comprises or consists of a polypeptide sequence of SEQ ID No. 113 and the light chain variable domain comprises or consists of three complementarity-determining regions (LCDR1 - LCDR3) and four framework regions (LFR1 - LFR4), wherein LCDR1 comprises or consists of a polypeptide sequence of SEQ ID No. 114, LCDR2 comprises or consists of a polypeptide sequence of SEQ ID No. 115 and LCDR3 comprises or consists of a polypeptide sequence of SEQ ID No.
116.
21. A construct or polypeptide of any of claims 1 to 20 for use in the treatment of cancer (e.g., a tumor) in combination with radiotherapy, a cancer vaccine, or ADC.
22. A construct or polypeptide of any of claims 1 to 20 for use in the treatment of cancer (e.g., a tumor) in combination with an anti-CTLA-4 antibody, an anti-PD-L1 antibody, or an anti-PD-1 antibody.